SEARCH

SEARCH BY CITATION

References

  • 1
    van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002; 13: 1359.
  • 2
    Vergeer M, Dallinga-Thie GM, Dullaart RPF, van Tol A. Evaluation of phospholipid transfer protein as a therapeutic target. Fut Lipidol 2008; 3: 32735.
  • 3
    Tzotzas T, Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Rev 2009; 10: 40311.
  • 4
    Borggreve SE, de Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33: 105169.
  • 5
    Jiang XC, Qin S, Qiao C et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7: 84752.
  • 6
    Lie J, de Crom R, van Gent T et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res 2002; 43: 187580.
  • 7
    Schneider M, Vergès B, Klein A et al. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 2004; 53: 26339.
  • 8
    Cheung MC, Vaisar T, Han X, Heinecke JW, Albers JJ. Phospholipid transfer protein in human plasma associates with proteins linked to immunity and inflammation. Biochemistry 2010; 49: 731422.
  • 9
    Schlitt A, Bickel C, Thumma P et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 185762.
  • 10
    de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BHR, van Tol A, Dullaart RPF. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006; 49: 398404.
  • 11
    Schgoer W, Mueller T, Jauhiainen M et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis 2008; 196: 21926.
  • 12
    Schlitt A, Blankenberg S, Bickel C et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res 2009; 50: 7239.
  • 13
    Engler MB, Pullinger CR, Malloy MJ et al. Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemia. Metabolism 2008; 57: 171924.
  • 14
    Bossé Y, Bouchard L, Després JP, Bouchard C, Pérusse L, Vohl MC. Haplotypes in the phospholipid transfer protein gene are associated with obesity-related phenotypes: the Québec Family Study. Int J Obes (Lond) 2005; 29: 133845.
  • 15
    Jarvik GP, Rajagopalan R, Rosenthal EA et al. Genetic and nongenetic sources of variation in phospholipid transfer protein activity. J Lipid Res 2010; 51: 98390.
  • 16
    Vergeer M, Boekholdt SM, Sandhu MS et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010; 122: 4707.
  • 17
    Riemens S, van Tol A, Sluiter W, Dullaart RPF. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998; 140: 719.
  • 18
    Riemens SC, van Tol A, Sluiter WJ, Dullaart RPF. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes 1999; 48: 16317.
  • 19
    Riemens SC, van Tol A, Sluiter WJ, Dullaart RPF. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients. Diabetologia 1998; 41: 92934.
  • 20
    Kaser S, Sandhofer A, Föger B et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 2001; 44: 11117.
  • 21
    Dullaart RPF, de Vries R, Dallinga-Thie GM, van Tol A, Sluiter WJ. Plasma cholesteryl ester transfer protein mass and phospholipid transfer protein activity are associated with leptin in type 2 diabetes mellitus. Biochim Biophys Acta 2007; 1771: 1138.
  • 22
    Dullaart RPF, de Vries R, Dallinga-Thie GM, Sluiter WJ, van Tol A. Phospholipid transfer protein activity is determined by type 2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminases. Clin Endocrinol (Oxf) 2008; 68: 37581.
  • 23
    Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF. Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma lecithin: cholesterol acyltransferase, phospholipid transfer protein, and cholesteryl ester transfer protein activities. J Lipid Res 1999; 40: 145966.
  • 24
    Murdoch SJ, Kahn SE, Albers JJ, Brunzell JD, Purnell JQ. PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity. J Lipid Res 2003; 44: 170512.
  • 25
    Laimer MW, Engl J, Tschoner A et al. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids 2009; 44: 112530.
  • 26
    Tzotzas T, Dumont L, Triantos A et al. Early decreases in plasma lipid transfer proteins during weight reduction. Obesity (Silver Spring) 2006; 14: 103845.
  • 27
    Oomen PH, van Tol A, Hattori H, Smit AJ, Scheek LM, Dullaart RPF. Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus. Diabet Med 2005; 22: 76874.
  • 28
    Tu AY, Albers JJ. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 2001; 50: 18516.
  • 29
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24: 133541.
  • 30
    Dallinga-Thie GM, van Tol A, Hattori H, Rensen PC, Sijbrands EJ. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E? Diabetes 2006; 55: 14916.
  • 31
    Grundy SM, Cleeman JI, Daniels SR et al. ; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 273552.
  • 32
    van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 12935.
  • 33
    Speijer H, Groener JE, van Ramshorst E, van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 1991; 90: 15968.
  • 34
    Selvin S. Statistical Analysis of Epidemiological Data. New York: Oxford University press, 1996.
  • 35
    Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 3948.
  • 36
    Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 2000; 1500: 8896.
  • 37
    Frayn KN, Williams CM, Arner P. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin Sci (Lond) 1996; 90: 24353.
  • 38
    Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003; 41: 112030.
  • 39
    Cao G, Beyer TP, Yang XP et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002; 277: 395615.
  • 40
    Goldstein JL, Brown MS, Liang G. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem 2010; 285: 680110.
  • 41
    Dullaart RPF, Hoogenberg K, Dikkeschei BD, van Tol A. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994; 10: 15815.
  • 42
    Tan KC, Shiu SW, Wong Y, Tam S. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005; 178: 36570.
  • 43
    Jänis MT, Metso J, Lankinen H et al. Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 2005; 331: 33340.
  • 44
    Settasatian N, Barter PJ, Rye KA. Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. J Lipid Res 2008; 49: 11526.